COVID-19 vaccine developed by China's CanSino to continue advancing phase-3 trials: report
BEIJING - China's CanSino Biologics Inc has got green light to continue phase-3 trials of its COVID-19 vaccine with the support of findings of an independent data monitoring committee, said recent media reports.
The independent committee "found the drugmaker's COVID-19 vaccine met its pre-specified primary safety and efficacy targets under an interim analysis of phase-3 trial data," Reuters cited the biopharmaceutical company to report on Monday.
"No adverse events related to the vaccine had occurred," the report said.
The vaccine candidate, referred to as Ad5-nCoV, is developed by CanSino Biologics Inc and the Academy of Military Sciences in China.
CanSino was approved to conduct phase-3 clinical trials in some countries in Europe and Asia, Wu Yuanbin, an official with China's Ministry of Science and Technology, said in September last year.
- Former Inner Mongolia Party chief expelled from CPC
- Snow leopard repeatedly spotted in Gansu's Qilian Mountains
- Study links disrupted brain iron metabolism to common psychiatric disorders
- China advances international commercial dispute resolution
- FAST telescope's new discovery reshapes understanding of early universe
- Xi extends Teachers' Day greetings, urges nurturing capable youth for national rejuvenation
